Indoco Remedies Sells Eye Unit for ₹110 Crore

Indoco Remedies' Board of Directors has approved the sale of its Ophthalmic Division to Sunways (India) Private Limited for ₹110 crore. This strategic move is structured as a slump sale, aiming to sharpen Indoco's focus on its core therapeutic areas.

Transaction Details

The division, considered non-core, contributed about 3.2% to Indoco's standalone revenue in FY25, representing ₹47.79 crore against the company's total standalone revenue of ₹1,494.78 crore. The transaction is expected to be finalised within three months, contingent on fulfilling certain conditions outlined in the transfer agreement.

Strategic Rationale

This divestment is designed to streamline Indoco Remedies' operations and allow it to concentrate resources on therapeutic areas with higher growth potential and strategic importance. The company anticipates this sharpened focus will improve operational efficiency and financial performance, particularly given its recent net losses.

Industry Context and Buyer

Indoco Remedies has historically developed and manufactured sterile ophthalmic products within this division. The sale aligns with a broader trend in the pharmaceutical sector where companies divest non-core assets to concentrate on specialized or innovative medicine segments. For example, Novartis previously divested ophthalmology brands to focus on innovative medicines. The buyer, Sunways (India) Private Limited, is a Mumbai-based eyecare product specialist, making it a strategic fit for the division.

Impact on Indoco Remedies

Following the sale, Indoco Remedies will receive ₹110 crore in cash, expected to strengthen its balance sheet. The company will sharpen its strategic focus on primary therapeutic segments, potentially improving resource allocation, and reduce operational complexity by exiting the ophthalmic segment. Shareholders can anticipate a more streamlined business model centered on core competencies.

Key Risks and Concerns

However, several risks warrant attention. Transaction completion depends on fulfilling specific conditions, which could lead to delays or complications. Indoco Remedies has reported net losses, including a significant ₹37.77 crore loss in FY25, and its net worth was negative ₹32.05 crore as of March 31, 2025. Auditors have raised concerns about the going concern status of two subsidiaries due to their negative net worth, flagging material uncertainty. The company has also faced low sales growth and a low interest coverage ratio, indicating ongoing financial challenges.

Competitor Landscape and Metrics

In the competitive Indian pharmaceutical landscape, Indoco Remedies' peers include Sun Pharmaceutical Industries, Divi's Laboratories, and Torrent Pharmaceuticals. For context, Sunways (India) Private Limited reported revenues of USD 15.85 million (approximately ₹137.42 crore) in FY24.

What to Watch

Investors will want to monitor the successful closure of the slump sale within the three-month period, plans for utilizing the ₹110 crore proceeds, and Indoco Remedies' strategy for improving profitability and addressing auditor concerns. Evaluating the performance of core therapeutic areas post-divestment will also be key.